BioWorld

March 8, 2002

Celgene Changing Course On Thalomid In Multiple Myeloma

Celgene Corp. is facing a delay in its new drug application for Thalomid after the FDA said it had to conduct a new trial in a different indication, but one that may be more lucrative over time. (BioWorld Today) Read More

Cubist Plans Cidecin NDA Filing This Year For Treating Infections

Besides Biting Fly, Parasitical Worm, River Blindness Needs Wolbachia Bacterial Infectivity

PDUFA Negotiations Likely To Lead To Increased Filing Fees

Other News To Note

Medicines Company Licenses Phase III Drug From AstraZeneca

U.S. Patent Disclosures

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Viva in vivo! At EHA, in vivo CAR T data continues to impress

BioWorld

Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...